were analyzed using both methods. For a representative patient, over 90% of the elemental lutetium in plasma could be ascribed to intact MLu at early time points. This percentage decreased to 59% at 48 hours after dosing, suggesting that some degradation and/or metabolism of the drug may have occurred.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and inductively coupled plasma-atomic emission spectroscopy (ICP-AES) methods were developed and validated for the evaluation of motexafin lutetium (MLu, lutetium texaphyrin, PCI-0123) pharmacokinetics in human plasma. The LC-MS/MS method was specific for MLu, whereas the ICP-AES method measured total elemental lutetium. Both methods were fast, simple, precise, and accurate. For the LC-MS/MS method, a closely related analogue (PCI-0353) was used as the internal standard (IS). MLu and the IS were extracted from plasma by protein precipitation and injected onto an LC-MS/MS system configured with a C18 column and an electrospray interface. The lower limit of quantitation was 0.05 μg MLu mL -1 , with a signal-to-noise ratio of 15:1. The response was linear from 0.05 to 5.0 μg MLu mL -1 . For the ICP-AES method, indium was used as the IS. The sample was digested with nitric acid, diluted, filtered, and then injected onto the ICP-AES system. Two standard curve ranges were validated to meet the expected range of sample concentrations: 0.5 to 50, and 0.1 to 10 μg Lu mL -1
INTRODUCTION
Texaphyrins are aromatic, pentadentate, porphyrin-like macrocyclic ligands that contain an expanded central core capable of forming highly stable 1:1 complexes with large cations such as trivalent lanthanides. [1] [2] [3] [4] [5] Motexafin lutetium (MLu) is the texaphyrin formed when Lu (III) is inserted into the texaphyrin macrocycle (Figure 1) . 6 When activated using far-red light (720-760 nm), MLu, a photosensitizer, produces highly toxic singlet oxygen capable of destroying diseased tissue. [7] [8] [9] [10] MLu is currently undergoing clinical evaluation for the photodynamic treatment of tumors, atherosclerosis, and age-related macular degeneration. 2, [11] [12] [13] [14] [15] [16] [17] Both clinical and nonclinical studies have been undertaken in order to elucidate the effect of dose on the pharmacokinetics and/or efficacy of MLu in biological systems. Bioanalytical methods developed in support of these studies have used scintillation counting (for studies using 14 C-radiolabeled compound 6 ), total fluorescence, [18] [19] [20] [21] and high-performance liquid chromatography (HPLC). evaluation of MLu pharmacokinetics in human plasma. The LC-MS/MS method was developed specifically for MLu and is particularly advantageous compared to other HPLC methods because the mass spectrometer provides an extra degree of selectivity for MLu. This added selectivity reduces the possibility that any degradation products or metabolites of MLu will interfere with MLu quantitation. If new metabolites of MLu are subsequently discovered in plasma, an LC-MS/MS method is generally easier to adapt for simultaneous quantitation of these new metabolites, since chromatographic separation of the metabolites may not be required. In addition, the LC-MS/MS method has a run time of 3 minutes, which reduces the analytical instrument time nearly 7-fold when compared to HPLC using a standard absorbance detector. 22 The ICP-AES method measures the total amount of elemental lutetium in plasma. Because the plasma sample is digested before analysis, lutetium derived from intact MLu, metal-containing metabolites/degradation products, lutetium complexes with other molecules in plasma, and unbound lutetium are all included in the total amount of lutetium measured. If a good correlation between ICP-AES and LC-MS/MS methods can be established, ICP-AES may provide a rugged alternative to LC-MS/MS for estimating the amount of MLu in samples destabilized by exposure to light and/or inadequate storage conditions. ICP-AES-based methods would also be useful in a mass balance study in which the total recovery of Lu (III) in urine and feces is measured as a percentage of the administered dose.
Individual assays for MLu and total elemental lutetium in human plasma provide important information that is needed for a more complete understanding of MLu pharmacokinetics. If the total amount of elemental lutetium in plasma can be accounted for as intact MLu, it would demonstrate stability of the compound in the body. If more elemental lutetium is found in plasma than can be attributed to MLu, it would suggest that the drug has been metabolized and/or degraded and could provide important information on the molecular species of Lu (III) in circulation after dosing. Since the biological activity of texaphyrins is dependent on the central metal cation, any process that causes Lu (III) to be dissociated from MLu could alter the activity and/or biodistribution of the compound. Another group has applied a similar approach for quantitation of gadodiamide and gadolinium in serum by HPLC and ICP, respectively. Their results showed good agreement between total gadolinium and gadodiamide levels in clinical study samples, indicating the absence of significant metabolites in serum for gadodiamide. 23 Both the LC-MS/MS and the ICP-AES methods are ideal for use in preclinical and clinical studies. These assays require small amounts of plasma, use a simple sample preparation procedure, and have short run times. A full validation of both methods resulted in assays that were sensitive, accurate, rugged, and reproducible. Trending analysis revealed that accuracy and reproducibility were maintained throughout months of clinical studies. The utility of the LC-MS/MS and ICP-AES methods was demonstrated by using both assays to analyze each plasma sample from a single representative patient.
MATERIALS AND METHODS

Instrumentation
LC-MS/MS
An Applied Biosystem MDS Sciex (Concord, Ontario, Canada) API 365 LC-MS/MS system was used. The analytical column was a Zorbax Eclipse XDB-C18 column, 150 × 3.0 mm (3.5 μm), from Agilent (Palo Alto, CA). The precolumn was BDS Hypersil C18, 10 × 2 mm (3 μm), from Keystone (Bellefonte, PA), which was changed before each batch run. The mobile phase was acetonitrile-ammonium acetate (100 mM, pH 4.3) 40:60 (vol/vol). The flow rate was 0.5 mL min 
ICP-AES
A PerkinElmer (Norwalk, CT) Optima ICP-AES instrument model 3000 XL was used. The radio frequency (RF) power was set at 1300 W, nebulizer flow at 0.500 L min -1 , auxiliary flow at 0.7 L min -1 , and plasma flow at 15 L min -1 . High-purity argon gas was used with head pressure at 80 psi. A cross-flow pneumatic GemTip nebulizer, model N058-0613, was used. The peristaltic pump from Cole Palmer (Vernon Hills, IL), Masterflex Model 7520-25, was set at a 600-speed setting. The autosampler was a Cetac ASX-500 from Cetac Technologies (Omaha, NE). A rinse solution of 10% nitric acid was used. Temperature was maintained at 16 C with a Coolflow CFT-33 refrigerated recirculator from Neslab (Portsmouth, NH). The element Lu261 at peak wavelength of 261.54 nm was read with a peak window of 0.0241; the upper interval was set to 0.040, and the lower interval was set to 0.048. The peak wavelength of the IS element indium was 325.609 nm and read with a peak window of 0.0297; the upper interval was set to 0.050, and the lower interval was set to 0.040. The viewing height was set at 15 nm, sam- 
Materials
MLu
MLu (PCI-0123), lot SA701, purity 91.3%, was supplied by Pharmacyclics, Inc (Sunnyvale, CA).
PCI-0353, Lot 202-050
The PCI-0353 IS (bis(acetato-O) [9,10- (Figure 2) . Briefly, the nonaromatic macrocyclic ligand (3.0 g, 3.1 mmol), Lu (III) acetate hydrate (1.67 g, 3.91 mmol), and triethylamine (3.5 mL, 25 mmol) were mixed together in methanol (600 mL) and heated to reflux while left exposed to air. The general procedure previously reported was used, 6, 24 and the reaction was deemed complete after 7 hours; workup and recrystallization from ethanol/isopropyl alcohol (IPA) afforded 1. 14 .37. The purity of PCI-0353 was checked using HPLC analysis (ie, >90% relative purity) using a similar method previously reported for MLu. 6 UV-visible spectra were obtained on a Hitachi-U3000 spectrophotometer (San Jose, CA). The relative purity was determined by HPLC analysis on the Waters Alliance HPLC system with Millennium Software (Milford, MA). Electrospray ionization mass spectrometry analysis was carried out on a Agilent HPLC 1100 (Palo Alto, CA) with a Thermo-Finnigan LCQ ion trap mass spectrometer (San Jose, CA). Schwarzkopf Microanalytical Laboratory (Woodside, NY) performed the elemental analysis of PCI-0353. All solvents were of reagent-grade quality and purchased commercially. Lutetium acetate was purchased from Alfa AESAR (Ward Hill, MA).
Other Materials
Lu and Indium (In) ICP standards for the ICP-AES analysis were purchased from GFS Chemicals (Powell, OH). All chemicals used were analytical or HPLC grade. The organic solvents, concentrated nitric acid, and 30% hydrogen peroxide were from Fisher (Fair Lawn, NJ). Glacial acetic acid, ammonium acetate, and HPLC-grade water were from Mallinckrodt (Paris, KY). Mobile phases were vacuum-filtered through 0.45-μm nylon membranes from Gelman Sciences (Ann Arbor, MI). Deionized water was prepared inhouse using a NANOpure water purification system from Barnstead (Dubuque, IA). Ethylenediamine-tetraacetic acid, disodium salt (EDTA-Na 2 ) and heparin-treated plasma, serum, and heparin-treated whole blood for control samples were purchased from Nashville Biological (Cincinnati, OH) and Biochemed Pharmacologicals, Inc (Winchester, VA).
Preparation of Solutions
LC-MS/MS
All solutions of MLu were prepared in polypropylene containers to avoid adsorption of MLu to glass. Primary stock solutions for standards and quality control (QC) samples were prepared from separate weighings. were prepared by further dilution of the high-QC sample with human plasma. Aliquots of standards and QC samples were distributed into polypropylene tubes and stored at -70°C.
ICP-AES
The method was developed and validated for samples in human EDTA plasma and further validated to include heparinized plasma, serum, and heparinized whole blood. A series of working standards was prepared by dilution of a 1000-ppm Lu ICP standard with water. These solutions were stored at 2 to 8°C in polypropylene tubes and were diluted 10-fold before analysis with control plasma, serum, or whole blood. Two standard ranges were used. The high-range standard concentrations were 50, 40, 30, 20, 10, 3.0, 1.0, and 0.5 μg mL . They were aliquoted into polypropylene tubes and stored at -20°C. For the IS, a 10 000-ppm indium ICP standard was used without dilution for the high standard range and diluted to 2000 ppm with water for the low standard range.
All QC samples were stored with the clinical samples until assayed. Some QC samples were reserved and stored separately for long-term storage stability tests. A set of calibration standards were placed near the beginning of each run before at least six replicates of QC samples, which were scattered among test samples (eg, tests of recovery, stability, selectivity). The length of some of the validation runs was designed to mimic the length of a clinical sample analysis.
Sample Processing Procedures
LC-MS/MS
Samples were processed under yellow light. Exactly 200 μL of each QC sample, analytical sample, or standard was added to a 1.5-mL microcentrifuge tube. After 20 μL of the IS and 0.8 mL of 1M acetic acid in acetonitrile were added, the tubes were vortexed for approximately 15 seconds, then set in a refrigerator for 30 minutes. They were then centrifuged for 15 minutes and transferred onto the LC-MS/MS in amber autosampler vials with plastic inserts for injection.
ICP-AES
Each QC sample, analytical sample, or standard was pipetted (0.5 mL) into a 16 × 100 mm screw-cap tube. After the addition of 50 μL of the IS, the solution was mixed and 1 mL of concentrated nitric acid was added, followed by 0.5 mL of 30% hydrogen peroxide. The tubes were digested for 60 minutes at 120°C. After cooling, 6 mL of water was added and the contents were vortexed and filtered through SA720 filter paper (Schleicher & Schuell, Keene, NH) into a 13 × 100 mm tube, in preparation for injection onto the ICP-AES.
Data Regression
The LC-MS/MS chromatograms were integrated using MacQuan software from Applied Biosystem MDS Sciex. For ICP, integration of the emission counts was performed on the PerkinElmer ICP-AES with a Digital DEC PC. All integrated data were transferred into a VAX/VMS Oracle database for regression. The peakarea ratio of analyte to the IS (y) was plotted against analyte concentration (x). A linear regression with 1/x weighting was used to determine slopes, intercepts, and correlation coefficients. MLu was calculated by multiplying the μg mL -1 concentration by a factor of 6.66.
RESULTS
LC-MS/MS
Method Development
Choice of IS and MS Parameters. The IS used for LC-MS/MS (PCI-0353) is a chemical analogue of MLu with an extra ethyl ether group in the side chain. The chemical similarity enables the IS and the analyte to behave similarly during sample processing, chromatography, ionization at the interface of the LC/MS, fragmentation, and detection in the mass spectrometer. Two acetate counterions are associated with 1 molecule of MLu or the IS to form a complex structure ( Figure  1 ).
The Q1 (parent) mass spectrum of MLu in Figure 3A showed 2 ions, m/z 1106.5 and 524.1, from MLu. The m/z 1106.5 ion is a singly charged ion, and the mass matches the complex losing 1 acetate counterion. The ion with m/z 524.1 is a doubly charged ion based on 0.5 mass differences between isotope peaks (insert of Figure 3A) , and it is an MLu 2+ ion without both acetate counterions. The abundance ratio of m/z 524.1 to 1106.5 remained 5.5:1 with various declustering potentials up to 70 V, which indicates that the dissociation of acetate counterions happened in the liquid phase rather than in the gas phase. The remaining single Oac MLu (or IS) complex was very stable under collisionactivated dissociation conditions and showed no fragment ions, including m/z 524.1 with collision potential up to 60 V (collision energy 60 eV for a singly charged ion) in the product ion spectrum (Figure 3B) . The collision gas used was N 2 . The signal of parent ion m/z 1106.5 significantly dropped when applying collision energy above 60 eV and still showed no fragmentation. The product ion spectrum of m/z 524.1 showed the same pattern of no fragmentation. However, the ion signal disappeared when applying collision potential more than 30 V, which transferred 60 eV collision energy to the doubly charged ion of m/z 524.1.
Under the MRM of mass spectrometer, the parent and product ions of the compounds of interest retained the same m/z of 1106 and 1150 for MLu and the IS, respectively. With high collision potential (60 V), the background noise was minimized by fragmenting potential interfering ions to different product ions, resulting in a good signal-to-noise ratio for sensitivity and selectivity. The same strategy has been used in our laboratory in LC-MS/MS bioanalytical methods for hard-to-fragment analytes to minimize background noise. 25, 26 Chromatograms of MLu and the IS in extracted plasma solutions are shown in Figure 4 . The compounds have the same retention time. The IS m/z was distinctly different from that of the analyte.
Sample Extraction. The Lu (III) metal ion positioned within the MLu macrocycle imparts a net 2+ charge to the molecule, which results in coordination with negatively charged counterions present in solution. Because of the polar nature of MLu, liquid/liquid extraction using an organic solvent was not attempted. Solid-phase extraction on an Oasis HLB cartridge was attempted using a buffered 50% acetonitrile mixture to elute the compounds, resulting in poor, inconsistent recovery and a noisy baseline in the LC-MS/MS chromatogram. Therefore, an acetonitrile protein precipitation method previously developed for the analysis of an analogous metallotexaphyrin was adapted for the quantitation of MLu. Acetonitrile was our first choice because an extract of aqueous acetonitrile solution could be directly injected onto the LC-MS/MS system and was also compatible with the LC mobile phase. Plasma samples could have been precipitated with an acid, such as perchloric acid, but the resulting extract would not have been compatible with the LC-MS/MS and may have resulted in severe matrix suppression.
Acidification of the acetonitrile with acetic acid resulted in a good MS signal. Both ammonium acetate and acetic acid were tested in the precipitation mixture; better peak shape was seen with the acetic acid. MLu was known to adhere to glass, so polypropylene microfuge tubes were chosen for the sample preparation; they could be subjected to higher g forces during centrifugation, resulting in a cleaner supernatant. Recovery of MLu from plasma samples was determined by comparing the MLu mass spectrometer response for plasma samples that were spiked and then extracted with the MS response seen for samples that were first extracted and then spiked.
The results for recovery and matrix effect are shown in Table 1 . With protein precipitation, MLu and the IS recoveries were high and consistent over the entire range of the method. The mean recovery was 86% for MLu and 87% for the IS. The coefficient of variation (CV) for the extracted samples was 8.0% for MLu and 13.0% for the IS. Matrix enhancement was seen in the presence of plasma for MLu (7%-17%) and the IS (15%).
Chromatography. Since a sufficient and consistent signal was seen with simple protein precipitation, chromatographic resolution of analytes from interfering species in the matrix was subsequently addressed. Ionization of analytes could be suppressed by other competing ions from the sample matrix, especially when electrospray was used. [25] [26] [27] [28] [29] It was important to provide separation of the analyte from interfering matrix components. Various columns were tested, and the analytical column selected provided adequate separation of the analyte from the majority of the interfering species in the matrix. Initially, a Keystone Inertsil ODS2 silica column (50 × 3 mm, 5 μm) was used; however, interfering late-eluting matrix peaks were seen. Increasing the column size to 100 × 4.6 mm, 5 μm bead size, did not increase the resolution of analyte peaks from interfering peaks. An isocratic system using a Zorbax Eclipse XDB-C18 column and mobile phase consisting of acetonitrile:ammonium acetate buffer (100 mM, pH 4.3) (60:40, vol/vol) was tried. This set of chromatographic conditions yielded acceptable separation of analyte peaks from interfering peaks. Most of the hydrophilic components in the plasma were eluted in the solvent front. However, the matrix effect was not completely eliminated. Although the major signalsuppressing components from the matrix were separated from the analyte, a slight but consistent matrix enhancement of the analyte response was observed.
Validation Performance
Sensitivity and Selectivity. The accuracy of the method was expressed as the percent relative error (RE), which was calculated as follows: (measured concentration-theoretical concentration)/theoretical concentration x 100. The precision was expressed as the CV. Table 2 shows lot-to-lot accuracy and precision data calculated from 10 independent lots of plasma. Also shown are the accuracy and precision data for a single lot of plasma spiked to a final concentration of 0.05 μg mL -1 (Lower Limit of Quantitation [LLOQ]) and analyzed 6 times as part of a single analytical run. To test lot-to-lot matrix effect on sensitivity and selectivity, 10 individual lots were tested after spiking with the analyte at concentrations of 0, 0.05, and 1 μg mL -1 . No individual lot showed any interference at the retention times of the compounds of interest. The signal-to-noise ratio was at least 15:1 at the LLOQ. The CV and RE of the mean concentra- *CV indicates coefficient of variation; IS, internal standard; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MLu, motexafin lutetium. MLu (0.05, 0.5, and 5.00 μg mL -1 ) and IS in human plasma samples were extracted by protein precipitation. For each analyte, the extraction recovery was calculated by comparing the peak area in samples spiked prior to processing (extracted) with equivalently treated samples spiked after processing (recovery control). The matrix effect was calculated by comparing the peak area of each analyte in samples spiked after processing (recovery control) to samples spiked into a matrix-free solution (neat). The mean (CV [%]) for 6 determinations (MLu) or 18 determinations (IS) was reported for each concentration tested. The percent recovery was calculated as C/B x 100. The percent matrix effect was calculated as (B/A -1) x 100. tion calculated from the 10 lots of plasma spiked at the LLOQ were 4.2% and -7.6%, respectively. Therefore, among the 10 matrix lots, there were no major differences that significantly affected the accurate quantification of MLu. The CV and RE of the mean concentration calculated from 6 replicate analyses of a single lot of plasma were 3.8% and -3.4%, respectively, which met the pharmaceutical industry's acceptance criteria of less than or equal to ±20% for bias and imprecision at the LLOQ. 30 Several plasma lots were pooled for preparation of standards and QC samples. Representative chromatograms of the LLOQ compared to the blank control plasma are shown in Figure 5 . The signal-to-noise ratio at the LLOQ for the pooled lot used for standard preparation was 15:1. Processed spiked samples containing only the IS had an interfering peak detected as MLu in some of the assay curves. When present, the interference peak quantitated between 5% and 12.6% runs, which were performed on 2 LC-MS/MS systems, by 2 analysts, over 12 days. For the backcalculated values of all plasma standards at each concentration level, the interday CV was 6.3% and the interday RE was within 8.4%. Six replicate injections of plasma QC samples at each of 3 concentrations levels were also included in these 5 validation runs. As shown in Table 4 (A columns), the interday CV was 6.3% and the interday RE was within 2.2%; the intraday CV was 3.2% and the intraday RE was within 3.5%.
ICP-AES
Method Development
Signal Optimization. The emission line used for MLu is 1 of 4 primary lines available, of which the strongest was chosen. Interference, signal strength, and sensitivity were optimized when using this primary line. For In, only 2 primary lines were available. The second strongest line was chosen because it yielded the optimum condition for good sensitivity and minimal interference. Heparinized plasma, heparinized whole blood, and serum were also tested and observed to be free of interference.
Validation Performance
Linearity, Bias, and Precision. Two standard curve ranges were validated in EDTA human plasma to meet the expected range of sample concentrations from different clinical protocols: 0.5 to 50 and 0.1 to 10 μg Lu mL -1 . For 6 EDTA human plasma standard curves prepared over the high concentration range, the mean coefficient of determination (r 2 ) ± SD was 0.99995 ± 0.00006 and the mean slope was 0.1018 mL μg -1 , with 2.7% CV. The interday CV was 1.5% and the interday RE was within 2.4% for the back-calculated values of all plasma standards at each concentration level ( Table 3 , B columns). For 5 human plasma standard curves prepared over the low concentration range, the mean coefficient of determination (r 2 ) ± SD was 0.99986 ± 0.00010 and the mean slope was 0.5764 mL μg -1 , with 1.0% CV. The interday CV was 2.8% and the interday RE was within 0.9% for the mean backcalculated values of all plasma standards at each concentration level ( Table 3 , C columns).
For both the high concentration range and the low concentration range, a set of validation samples were prepared at the LLOQ and QC samples were prepared at 3 concentration levels spanning the linear range of the method. For the high concentration range LLOQ validation samples (0.5 μg mL -1 Lu), the intraday CV was 3.7% and the intraday RE was 10.5%, n = 14. For all other QC samples in the high concentration range, the interday CV was 8.7% and the interday RE was within 4.3%; the intraday CV was 5.2% and the intraday RE was within 6.6% (Table 4, B columns). For the low concentration range LLOQ validation samples, the intraday CV was 4.9% and the RE was 4.9%. For all other QC samples in the low concentration range, the interday CV was 1.5% and the interday RE was within 5.3%; the intraday CV was 2.0% and the intraday RE was within 4.7% (Table 4 , C columns).
The ICP-AES method was also validated over the low concentration range in heparinized whole blood. For 5 validation batches analyzed over 3 days, the mean (CV) coefficient of determination (r 2 ) ± SD was 0.99964 ± 0.00036 and the mean slope was 0.5451 mL μg -1 , with 5.0% CV. For the mean back-calculated values of all plasma standards at each concentration level, the interday CV was 4.4% and the interday RE was within 2.0% (Table 3, D columns) . A set of QC samples was prepared at 3 concentration levels spanning the linear range of the method. These QC samples were also analysed as part of the validation. For the QC samples, the interday CV was 2.8% and the interday RE was within 2.9%; the intraday CV was 1.3% and the intraday RE was within 3.7%. In addition, a dilution QC sample was prepared at 25 μg mL -1 and diluted (n = 6 replicate dilutions) to fall within the linear range of the assay. The interday CV was 2.7% and the interday RE was 2.6%; the intraday CV was 2.6% and the intraday RE was 3.0% (Table 4 , D columns).
The ICP-AES method was extended at the low concentration standard curve range (0.1-10 μg Lu mL -1 ) to include heparinized plasma and serum in addition to EDTA plasma. For the cross-comparison, the QC samples were prepared in heparinized plasma and serum at the same 3 concentration levels in each matrix. The concentration for each QC sample was first backcalculated using a standard curve prepared in EDTA plasma, then back-calculated again using a matrixmatched standard curve. At each concentration level, the 2 sets of back-calculated values differed by less than 0.9%.
Analyte Stability
Stability of the MLu was a concern because preliminary data indicated that the compound was lightsensitive. Because MLu could generate reactive oxygen species upon exposure to visible light, it was important to protect samples from light after collection and during processing and storage. Therefore, the stability of MLu in plasma was tested before and after extraction using the LC-MS/MS method. When processed under either fluorescent or yellow light, MLu was stable in the plasma matrix for at least 4 hours at room temperature, 15 hours under refrigeration, and 23 months at 70°C ( Table 5 ). The plasma samples could be subjected to at least 6 cycles of freezing and thawing without the loss of MLu potency. After extraction, MLu was stable on the autosampler tray for 125 hours in the reconstitution solvent, as determined by reinjection stability. The extracted samples could also be stored in a refrigerator for at least 57 hours before injection.
Method Robustness
For some of the validation runs, a second LC-MS/MS system (Applied Biosystems/MDS Sciex API 365 platform and associated HPLC system) was used to ensure method ruggedness on multiple platforms. During the validation, 2 analytical columns were tested between the 2 systems, resulting in similar chromatographic performance, with a CV of 5.0% and an RE of 6.5% for all batches. In subsequent clinical sample analysis, 4 additional columns were used with consistent chromatographic performance. Three different analysts performed extractions during the validation. Results of these extractions yielded a CV of 4.0% and an RE of 6.0% among analysts. Since the validation, 8 additional analysts have been validated to assay clinical samples.
Application to Clinical Sample Analysis
A pharmacokinetic study of photoangioplasty in subjects with peripheral arterial disease was conducted in 47 individuals (34 males and 13 females). In this clinical safety trial, subjects received Antrin (MLu) injection as a single intravenous infusion (1-5 mg kg -1 ). Plasma or serum samples were obtained at baseline and at 2 to 11 serial time points obtained over 6 days after dosing.
MLu and total elemental lutetium concentrations in plasma were measured using LC-MS/MS and ICP-AES, respectively. To facilitate comparison with the LC-MS/MS data, elemental lutetium concentrations (determined by ICP-AES) were converted to equivalent concentrations of MLu before pharmacokinetic analysis. Figure 6 shows concentration-time data derived from a representative patient enrolled in the trial. This patient received a single intravenous 10-minute infusion of 3 mg kg -1 MLu. As shown in Figure 6 , both methods yielded similar values for C max (35.1 μg-equiv mL -1 MLu and 33.4 μg mL -1 MLu for ICP-AES and LC-MS/MS, respectively), indicating that 95% of the total elemental lutetium in the plasma sample corresponding to t max could be attributed to MLu. As indicated in Figure 7 , this percentage decreased to 59% at 48 hours postdosing, suggesting that degradation products and/or metabolites of MLu may exist in plasma samples obtained at later time points. These degradation products/metabolites could result from slow degradation/metabolism of the compound in plasma/tissue, enterohepatic uptake of elemental lutetium following biliary elimination, and/or a tissue compartment associated with slow elimination of elemental lutetium. However, because of the rapid initial clearance of the drug from plasma, lutetium derived from species other than MLu did not make a major contribution to the area under the curve (AUC). Using noncompartmental analysis, AUC 0-48 hour was calculated based on plasma MLu concentration-time data (LC-MS/MS) and found to equal 183.9 μg•hr mL -1 . The result was divided by the corresponding value calculated using ICP-AESderived elemental lutetium concentration-time data, after converting lutetium concentrations to equivalent concentrations of MLu (255.7 μg-equiv•hr mL -1 ). This ratio, expressed as a percentage, revealed that during the 48-hour period following administration, 72% of the total systemic exposure to lutetium-containing species could be attributed to MLu.
CONCLUSION
LC-MS/MS and ICP-AES methods were developed and validated for the determination of MLu and elemental lutetium, respectively, in human plasma. These assays require small amounts of plasma, use a simple sample preparation procedure, and have rapid run times. A full validation of both methods revealed that the assays were sensitive, accurate, rugged, and reproducible. In addition, trending analysis revealed that accuracy and reproducibility were maintained throughout months of sample analyses. The utility of the LC-MS/MS and ICP-AES methods was demonstrated by using both assays to analyze each plasma sample from a single representative patient. The pharmacokinetic data indicated some degradation/metabolism of MLu in humans, but the majority of elemental lutetium in plasma was attributed to that contained in intact MLu.
